Previous 10 | Next 10 |
–Mitapivat Demonstrated a Statistically Significant Increase in Hemoglobin Response Rate Compared to Placebo – – Statistical Significance Also Achieved for Key Secondary Endpoints of Change From Baseline in Both FACIT-Fatigue Score and Hemoglobin Concentration &...
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 42 nd Annual J.P. Morgan Healthcare Conference o...
2023-12-10 07:30:00 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . For further details see: Wall Street Breakfast: The Week Ahead
– Treatment with Mitapivat Demonstrated Statistically Significant Improvement in Hemoglobin Response Compared to Placebo – – Improvements Observed in Annualized Rates of Sickle Cell Pain Crises, Markers of Hemolysis and Erythropoiesis in Participants Treated with Mi...
2023-12-08 15:00:12 ET More on the markets S&P 500: New All-Time Highs Before A Major Sell-Off S&P 500 Forecast 2024: Muddling Through Only Thing That Matters Is Price; Nasdaq Has Further To Go - Cestrian Capital Research Money market funds attract mo...
– 40 Percent of Low Transfusion Burden Cohort Achieved Transfusion Independence; One Study Patient Achieved Hemoglobin Response Endpoint – – Safety Profile Consistent with Data Reported in Healthy Volunteers Study – – Company Expects to Ini...
2023-11-20 04:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-02 11:34:05 ET Agios Pharmaceuticals Inc. (AGIO) Q3 2023 Earnings Conference Call November 2, 2023 8:00 am ET Company Participants Brian Goff - Chief Executive Officer Cecilia Jones - Chief Financial Officer Tsveta Milanova - Chief Commercial Officer ...
– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease, Compared to the Placebo Arm; Data Support Advancement to Phase 3 Portion of RISE UP – – Agios to Highlight Additiona...
2023-11-02 07:20:07 ET More on Agios Pharmaceuticals Agios Pharmaceuticals: Positive Phase 2 Results In Sickle Cell Study Agios Pharmaceuticals Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Agios Pharmaceuticals Historical earnings data for ...
News, Short Squeeze, Breakout and More Instantly...
Agios Pharmaceuticals Inc. Company Name:
AGIO Stock Symbol:
NASDAQ Market:
Agios Pharmaceuticals Inc. Website:
At the RBC Global Healthcare Conference, held on 14-15 May, RBC’s Healthcare Desk Sector Strategist gauged biotech investor sentime...
– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – – Additional P...
– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – – Additional Presentations to Highlight Quality of Life Data from ENERGIZE and Design of the Phase 3 RISE UP Study of Mitapivat in Sic...